Mylan Plans Launch Of Generic Duragesic Despite Pediatric Exclusivity
Executive Summary
Mylan is planning to launch its generic fentanyl transdermal system by July, the date of the original patent expiration for Alza's Duragesic, despite the product's six-month pediatric exclusivity extension
You may also be interested in...
J&J Duragesic Pediatric Exclusivity Blocks Mylan Generic Until January
Mylan's generic fentanyl transdermal patch is blocked from launching before January 2005 by J&J/Alza's six-month pediatric exclusivity on Duragesic, FDA said
J&J Duragesic Pediatric Exclusivity Blocks Mylan Generic Until January
Mylan's generic fentanyl transdermal patch is blocked from launching before January 2005 by J&J/Alza's six-month pediatric exclusivity on Duragesic, FDA said
J&J Headcount Reduction Program On Target; Company Posts Strong Quarter
Johnson & Johnson's headcount reduction program is on target, with 1,000 employees taking advantage of an early retirement option, CFO Robert Darretta said on an April 13 conference call